Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (abemaciclib, palbociclib, ribociclib) plus aromatase inhibitors (AI) are the modern standard-of-care of the first-line treatment of hormone-dependent (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).Aim. To evaluate the effects of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-05-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1348 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (abemaciclib, palbociclib, ribociclib) plus aromatase inhibitors (AI) are the modern standard-of-care of the first-line treatment of hormone-dependent (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).Aim. To evaluate the effects of using CDK4/6 inhibitors for treating patients with HR+/HER2– ABC on reducing overall cancer mortality in Russia.Materials and methods. Proposed mathematical model describes duration of therapy and treatment outcomes for AI alone or in combination with CDK4/6 inhibitors in patients with HR+/HER2– ABC. The model was based on overall survival and progression-free survival data from clinical trials and matching-adjusted indirect comparison. Frequency of drug prescriptions in both current and forecast practices was derived from regional surveys. The model was used to estimate the number of lives saved and healthcare system costs when transitioning from current practice to the forecast one by 2030, considering the number of adult patients with HR+/HER2– ABC, who may start considered therapy annually in Russia.Results. Annually, up to 10,794 patients with HR+/HER2– ABC in Russia are diagnosed and indicated for first-line therapy using CDK 4/6 inhibitors in combination with AI. However, 30 % of them are prescribed suboptimal AI monotherapy. Expanding CDK4/6 inhibitor usage in combination with AI to 83 % with the increase of using ribociclib and reallocating the prescription of drugs according to the forecast practice may lead to reduction in mortality from malignant neoplasms by 934 cases by 2030. Transitioning to the forecast therapy practice will require a 20 % increase in funding.Conclusion. The use of CDK4/6 inhibitors in patients with HR+/HER2– ABC has a significant and quantifiable impact on reducing cancer-related mortality in Russia. |
|---|---|
| ISSN: | 1994-4098 1999-8627 |